Major Research Areas

Selected Publications

Nasi ML, Meyers M, Livingston PO, Houghton AN, Chapman PB. Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside. Melanoma Res. 1997;7:S155-S162.

Soiffer RJ, Chapman PB, Murray C, Williams L, Unger P, Collins H, Houghton AN, Ritz J. Administration of R24 monoclonal antibody and low dose interleukin-2 for malignant melanoma. Clin Cancer Res. 1997;3:17-24.

Bowne WB, Srinivasan R, Wolchok JD, Hawkins WG, Blachere NE, Dyall R, Lewis JJ, Houghton AN. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med. 1999;190:1717-1722.

Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas K, Moynahan M, Houghton A, Norton L, Livingston PO. Vaccination of high-risk breast cancer patients with mucin-1 (MUCI) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res. 2000;5:1693-1701.

Kaminski MC, MacKenzie CR, Mooibroek MJ, Dahms TE, Hirama T, Houghton AN, Chapman PB, Evans SV. The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces. Demonstration of an intermolecular beta-sheet interaction between vh domains. J Biol Chem. 1999;274:5597-5604.

Dyall R, Bowne WB, Weber LW, LeMaoult J, Szabo P, Moroi Y, Piskun G, Lewis JJ, Houghton AN, Nikolic-Zugic J. Heteroclitic immunization induces tumor immunity. J Exp Med. 1998;188:1553-1561.

Hirschowitz E, Leonard S, Song W, Ferris B, Leopold PL, Lewis JJ, Bowne WB, Wang S, Houghton AN, Crystal RG. Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma. Gene Ther. 1998;5:975-983.

Weber LW, Bowne WB, Wolchok JD, Srinivasan R, Qin J, Moroi Y, Clynes R, Song P, Lewis JJ, Houghton AN. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest. 1998;102:1258-1264.

Ross, HM, Weber LW, Wang S, Piskun G, Dyall R, Song P, Takechi Y, Nikolic-Zugic J, Houghton AN, Lewis JJ. Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization. Clin Cancer Res. 1997;3:2191-2196.

Minasian LM, Yao TJ, Steffens TA, Scheinberg DA, Williams L, Riedel E, Houghton AN, Chapman PB. A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma. Cancer. 1995; 75:2251-2257.

Thomson TM, Real FX, Murakami S, Cordon-Cardo C, Old LJ, Houghton AN. Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. J Invest Dermatol. 1988;90:459-466.

Houghton AN, Eisinger M, Albino AP, Cairncross JG, Old LJ. Surface antigens of melanocytes and melanomas. Markers for melanocyte differentiation and melanoma subsets. J Exp Med. 1982;156:1755-1766.

McCaffrey M, Yao T-J, Williams L, Livingston PO, Houghton AN, Chapman PB. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: Enhanced immunogenicity when combined with adjuvant. Clin Cancer Res. 1996;2:679-686.

Naftzger C, Takechi Y, Kohda H, Hara I, Vijayasaradhi S, Houghton AN. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Nat Acad Sci USA. 1996;93:14809-14814.

Takechi Y, Hara I, Naftzger C, Xu Y, Houghton AN. A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin Cancer Res. 1996;2:1837-1842.

Boussiotis VA, Pardo NA, Collins H, Houghton A, Ritz J, Nadler LM, Soiffer RJ. R24 anti-GD3 ganglioside antibody can induce costimulation and prevent the induction of alloantigen-specific T cell clonal anergy. Eur J Immunol. 1996;26:2149-2154.

Yan X, Evans SV, Kaminki MJ, Gilles SD, Reisfeld RA, Houghton AN, Capman PB. Characterization of an Ig VH idiotype that results in specific homophilic binding and increased avidity for antigen. J Immunol. 1996;157:1582-1588.

Jakubowski AN, Bajorin DF, Templeton MA, Chapman PB, Cody BV, Thaler H, Tao Y, Filippa DA, Williams L, Sherman ML, Garnick MB, Houghton AN. Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma. Clin Cancer Res. 1996;2:295-302.

Brooks D, Taylor C, Dos Santos B, Linden H, Houghton A, Hecht TT, Kornfeld S, Taetle R. Phase Ia trial of murine immunoglobin A antitransferrin receptor antibody 42/6. Clin Cancer Res. 1995;1:1259-1265.

Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch J. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA. 1998;95:652-656.

Houghton AN, Vijayasaradhi S, Bouchard B, Naftzger C, Hara I, Chapman PB. Recognition of autoantigens by patients with melanoma. Ann of N Y Acad Sci. 1993;690:59-68.

Houghton AN, Gold JS, Blachere NE. Immunity against cancer: lessons learned from melanoma. Cur Opin Immunol. 2001;13:134-140.

Janetzki S, Song P, Gupta V, Lewis JJ, Houghton AN. Insect cells as HLA-restricted antigen-presenting cells for the IFN-gamma elispot assay. J Immunol Methods. 2000;234:1-12.

Chapman PB, Houghton AN. Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody. J Clin Invest. 1991;88:186-192.

Takahashi T, Chapman PB, Yang SY, Hara I, Vijayasaradhi S, Houghton AN. Reactivity of autologous CD4+ T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. J Immunol. 1995;154:772-779.

Chapman PB, Gillies SD, Houghton AN, Reilly RM. Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody. Cancer Immunol Immunother. 1994;39:198-204.

Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med. 1994;180:1-4.

Norihisa Y, McVicar DW, Ghosh P, Houghton AN, Longo DL, Creekmore SP, Black T, Ortaldo JR, Young HA. Increased proliferation, cytotoxicity, and gene expression after stimulation of human peripheral blood T lymphocytes through a surface ganglioside (GD3). J Immunol. 1994;152:485-495.

Minasian LM, Szatrowski TP, Rosenblum M, Steffens T, Morrison ME, Chapman PB, Williams L, Nathan CF, Houghton AN. Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma. Blood. 1994;83:56-64.

Wang Z, Cao Y, Albino AP, Zeff RA, Houghton AN, Ferrone S. Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in ß2-microglobulin messenger mRNA. J Clin Invest. 1993;91:684-692.

Bajorin DF, Chapman PB, Wong GY, Cody BV, Cordon-Cardo C, Dantes L, Templeton MA, Scheinberg D, Oettgen HF, Houghton AN. Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma. Melanoma Res. 1992;2:355-362.

Welte K, Miller G, Chapman PB, Yuasa H, Natoli E, Kunicka JE, Cordon-Cardo C, Buhrer C, Old LJ, Houghton AN. Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. J Immunol. 1987;139:1763-1771.

Hara I, Nguyen H, Takechi Y, Gansbacher B, Chapman PB, Houghton AN. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. Int J Cancer. 1995;61:253-260.

Gansbacher B, Zier K, Cronin K, Hantzopoulos PA, Houghton A, Gilboa E, Golde D. Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells. Blood. 1992;80:2817-2825.

Hara I, Takechi Y, Houghton AN. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med. 1995;182:1609-1614.

Yuasa H, Scheinberg DA, Houghton AN. Gangliosides of T lymphocytes: evidence for a role in T-cell activation. Tissue Antigens. 1990;35:47-56.

Vijayasaradhi S, Bouchard B, Houghton AN. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med. 1990;171:1375-1380.

Chapman PB, Yuasa H, Houghton AN. Homophilic binding of mouse monoclonal antibodies against GD3 gangliosides. J Immunol. 1990;145:891-898.

Vadhan-Raj S, Cordon-Cardo C, Carswell E, Mintzer D, Dantis L, Duteau C, Templeton MA, Ottegen HF, Old LJ, Houghton AN. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of an inflammatory response at tumor sites. J Clin Onc. 1988;6:1636-1648.

Lewis JJ, Janetzki S, Schaed S, Panageas KS, Wang S, Williams L, Meyers M, Butterworth L, Livingston PO, Chapman PB, Houghton AN. Evaluation of CD8(+) T cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int J Cancer. 2000;87:391-8.

Chang HR, Smelser S, Cardon-Cardo C, Houghton AN, Brennan MF. Expression and modulation of class I and class II histocompatibility leukocyte antigens on human soft tissue sarcomas. Cancer. 1993;72:2956-2962.

Return to Tumor Immunity, Autoimmunity, and Immune Surveillance of Genetic Integrity Main Page

Site Map \| Index	Legal Disclaimer \| Privacy Practices \| Public Notices

©2009 Memorial Sloan-Kettering Cancer Center. 212-639-2000 1275 York Avenue New York, NY 10065.	PublicAffairs@mskcc.org